our predictions for eyecare in 2022

2022 is looking like it could be an exciting year for the eyecare industry, with multiple innovations and treatments in the pipeline for the upcoming months. Let us know what you think could be the largest #eyecare industry advancements for 2022 by placing your opinion in the comments 👇
 
It is looking like this is the year for the start of the #presbyopia drops industry. Presbyopia, an age-related gradual loss of a persons near vision, effects 120 million people in the US alone. The current available treatments are glasses, contact lenses and surgery. The eyedrops industry is an exciting development in the treatment for patients with presbyopia. Contenders to keep an eye out for this year include: Allergan, Eyenovia Inc. and LENZ Therapeutics.
 
The market for #myopia treatment is becoming increasingly more competitive with more options available to help near sightedness. With Atropine eyedrops already licenced by companies such as Bausch + Lomb and Laboratoires Théa and a huge focus on Myopia management and correction from companies such as Essilor Group and CooperVision.
 
A couple of our news posts in 2021 looked at the development of #AI in diagnosing eye issues. This may gain momentum in 2022 because of the backlog of patients due to the current pandemic. AI offers the potential to increase patient flow and free up ophthalmologists’ time to enable them to treat diseases. Digital Diagnostics have developed an autonomous AI-based diagnostic system to detect diabetic retinopathy, a visual complication of diabetes. Topcon Healthcare and RetInSight have collaborated for AI-based eyecare solutions, allowing to detect and monitor to primary eye care providers, thereby aiding with patient management.
 
There is also a host of new retinal treatments for drugs and therapies to get regulatory approval, with the potential of some of these being commercially launched. ProQR Therapeutics are looking very close to the end of their Phase 2/3 trial on their treatment for Leber congenital amaurosis. They are also in the phase 2/3 trials for their treatment of retinitis pigmentosa and usher syndrome. Whilst Adverum Biotechnologies, Inc. Biotechnology are currently in their Phase 2 trial for their retinal pigmentosa treatments. Meanwhile LumiThera, Inc. are using a medical device based approach to treating dry AMD utlising photobiomodulation (PBM).